Literature DB >> 21178471

Candida infection and colonization among non-trauma emergency surgery patients.

Themistoklis Kourkoumpetis1, Dimitra Manolakaki, George Velmahos, Yuchiao Chang, Hasan B Alam, Marc M De Moya, Elizabeth A Sailhamer, Eleftherios Mylonakis.   

Abstract

BACKGROUND: Candida is a significant pathogen among critically ill patients. However, candidiasis among non-trauma emergency surgery (NTES) patients has not been previously investigated. Herein we describe the incidence of both colonization and infection from Candida and risk factors for invasive disease in this population.
METHODS: For this retrospective single center study we included all NTES patients with ICU stay ≥4 days from May 1(st), 2002 to April 30(th), 2007. Patients were divided into 3 non-overlapping groups: 1) patients with Candida-infection, 2) patients with Candida colonization and 3) patients with negative Candida cultures. Groups were compared by univariate and multivariate analyses to identify significant risk factors for invasive candidiasis.
RESULTS: Of all 289 eligible patients, 63 (21.7%) fulfilled the criteria for Candida infection and 110 (38%) were included in the Candida colonization group. Interestingly, from the 63 patients with invasive candidiasis, 25 (39.7%) were infected by a non-albicans species. Upon multivariate analyses, ventilator-associated pneumonia (VAP) (Odds Ratio [OR]: 2.34; 95%, Confidence Interval [CI]: 1.213-4.533, p = 0.0112), bacteremia (OR: 4.778; 95%CI: 1.519-15.029, p = 0.0075) and surgical complications (OR: 3.903; 95%CI: 1.335-11.412, p = 0.0129) were independent risk factors for the development of Candida infection. Candida infection and colonization were both found to correlate with approximately $40,000-100,000 mean additional costs). Interestingly, candidemia was associated with 63% all-cause mortality. For all other forms of candidiasis, mortality was not significantly different among groups.
CONCLUSION: We found that Candida infection is alarmingly high among NTES patients with prolonged intensive care unit (ICU) stay. Surgical complications and bacterial infections (VAP and bacteraemia) were significantly correlated with the development of candidiasis. Candidiasis reached a rate of 21.7/100 discharges, which is significantly higher than most established high-risk populations for candidiasis. Future studies should review the need for antifungal prophylaxis on this population.

Entities:  

Mesh:

Year:  2010        PMID: 21178471     DOI: 10.4161/viru.1.5.12795

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  16 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

Review 2.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 3.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

4.  Integrin Cross-Talk Regulates the Human Neutrophil Response to Fungal β-Glucan in the Context of the Extracellular Matrix: A Prominent Role for VLA3 in the Antifungal Response.

Authors:  Courtney M Johnson; Xian M O'Brien; Angel S Byrd; Valentina E Parisi; Alex J Loosely; Wei Li; Hadley Witt; Mohd H Faridi; Craig T LeFort; Vineet Gupta; Minsoo Kim; Jonathan S Reichner
Journal:  J Immunol       Date:  2016-11-16       Impact factor: 5.422

5.  Oral Candida albicans isolates from HIV-positive individuals have similar in vitro biofilm-forming ability and pathogenicity as invasive Candida isolates.

Authors:  Juliana C Junqueira; Beth B Fuchs; Maged Muhammed; Jeffrey J Coleman; Jamal M A H Suleiman; Simone F G Vilela; Anna C B P Costa; Vanessa M C Rasteiro; Antonio O C Jorge; Eleftherios Mylonakis
Journal:  BMC Microbiol       Date:  2011-11-04       Impact factor: 3.605

6.  Proanthocyanidins polymeric tannin from Stryphnodendron adstringens are active against Candida albicans biofilms.

Authors:  Raul Leal Faria Luiz; Taissa Vieira Machado Vila; João Carlos Palazzo de Mello; Celso Vataru Nakamura; Sonia Rozental; Kelly Ishida
Journal:  BMC Complement Altern Med       Date:  2015-03-19       Impact factor: 3.659

7.  MicroRNA Expression Profiling of Human Respiratory Epithelium Affected by Invasive Candida Infection.

Authors:  Syed Aun Muhammad; Nighat Fatima; Nawazish-I-Husain Syed; Xiaogang Wu; X Frank Yang; Jake Y Chen
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

8.  Medicinal potential of Morella serata (Lam.) Killick (Myricaceae) root extracts: biological and pharmacological activities.

Authors:  Anofi Omotayo Tom Ashafa
Journal:  BMC Complement Altern Med       Date:  2013-07-08       Impact factor: 3.659

9.  Diagnostic value of immunoglobulin G antibodies against Candida enolase and fructose-bisphosphate aldolase for candidemia.

Authors:  Fang-Qiu Li; Chun-Fang Ma; Li-Ning Shi; Jing-Fen Lu; Ying Wang; Mei Huang; Qian-Qian Kong
Journal:  BMC Infect Dis       Date:  2013-05-31       Impact factor: 3.090

10.  Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China.

Authors:  Chun-fang Ma; Fang-qiu Li; Li-ning Shi; Yu-an Hu; Ying Wang; Mei Huang; Qian-qian Kong
Journal:  BMC Infect Dis       Date:  2013-07-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.